Evidence map›Paper›PMID 41853739›Full record

ArticleClinical and translational radiation oncology2026

Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer - results from a European multicenter cohort study.

Sebastian Schäfer, Isabell Seiler, Lena Kästner, Johannes Meents, Marek Slavik, Petr Burkon, Mauro Loi, Pierluigi Bonomo, Camilla von Wachter, Panagiotis Balermpas and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Sebastian SchäferDepartment of Radiotherapy, University Hospital Leipzig, Stephanstraße 9a, Leipzig, Germany.
Isabell SeilerDepartment of Radiotherapy, University Hospital Leipzig, Stephanstraße 9a, Leipzig, Germany.
Lena KästnerDepartment of Radiation Oncology, University Medicine Mannheim, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, Mannheim, Germany.
Johannes MeentsDepartment of Radiation Oncology, University Medicine Mannheim, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, Mannheim, Germany.
Marek SlavikDepartment of Radiation Oncology, Masaryk Memorial Cancer Institute and Medical Faculty, Masaryk University, Brno, Czech Republic.
Petr BurkonDepartment of Radiation Oncology, Masaryk Memorial Cancer Institute and Medical Faculty, Masaryk University, Brno, Czech Republic.
Mauro LoiRadiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Pierluigi BonomoRadiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Camilla von WachterDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistr. 100, Zurich CH-8091, Switzerland.
Panagiotis BalermpasDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistr. 100, Zurich CH-8091, Switzerland.
Anna Sabrina SchunnDepartment of Radiotherapy and Radiation Oncology, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany.
Sophia DrabkeDepartment of Radiotherapy and Radiation Oncology, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany.
Richard HolyRadiotherapy Med 360 Grad in Aachen, Viehhofstraße 43, 52066 Aachen, Germany.
Kenneth KlischiesDepartment of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.
Olaf WittensteinDepartment of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.
Jochen WillnerDepartment of Radiotherapy, Klinikum Bayreuth GmbH, Preuschwitzer Str. 101, 95445 Bayreuth, Germany.
Andrea BaehrDepartment of Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Priska BankClinic for Radiation Therapy and Radio-Oncology Gera, Waldklinikum Gera, Germany.
Richard PartlDepartment of Therapeutic Radiology and Oncology, Comprehensive Cancer Center, Medical University of Graz, 8036 Graz, Austria.
Thomas MaderDepartment of Radiation Oncology, Kantonsspital Graubünden, Chur, Switzerland.
Bernd FrerkerDepartment of Radiation Oncology, Rostock University Medical Center, Rostock, Germany.
Fabian LohausDepartment of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstraße 74, Dresden, Germany.
Felix EhretEuropean Radiosurgery Center Munich, Munich, Germany.
Maike TrommerDepartment of Radiation Oncology, Faculty of Medicine and University Hospital Bonn, Bonn, Germany.
Eleni GkikaDepartment of Radiation Oncology, Faculty of Medicine and University Hospital Bonn, Bonn, Germany.
Alexander RühleDepartment of Radiotherapy, University Hospital Leipzig, Stephanstraße 9a, Leipzig, Germany.
Matthias GuckenbergerDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistr. 100, Zurich CH-8091, Switzerland.
Christos MoustakisDepartment of Radiotherapy, University Hospital Leipzig, Stephanstraße 9a, Leipzig, Germany.
Thomas BrunnerDepartment of Therapeutic Radiology and Oncology, Comprehensive Cancer Center, Medical University of Graz, 8036 Graz, Austria.
Oliver BlanckDepartment of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.
Judit Boda- HeggemannDepartment of Radiation Oncology, University Medicine Mannheim, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, Mannheim, Germany.
Nils H NicolayDepartment of Radiotherapy, University Hospital Leipzig, Stephanstraße 9a, Leipzig, Germany.
Franziska NäglerDepartment of Radiotherapy, University Hospital Leipzig, Stephanstraße 9a, Leipzig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: The interdisciplinary treatment concept for bone metastases (BoM) of oligometastatic breast cancer includes metastasis-directed radiotherapy. We evaluated oncological outcomes of BoM treated with stereotactic body radiotherapy (SBRT) in a large European cohort. Material and methods: Data of breast cancer patients treated with SBRT for BoM between 2010 and 2024 at 17 European cancer centers were retrospectively collected. Treatment and dose concepts were analyzed regarding their impact on freedom from local recurrence (FFLR), overall survival (OS), progression-free survival (PFS), and safety profile. Results: With a median follow-up of 29.6 months (interquartile range: 15.0-48.0), 109 patients with 147 BoM were analyzed. SBRT was performed with a prescribed dose of median 35 Gy in median 5 fractions. 1-/3-year FFLR for mean biologically effective dose (BED Conclusion: In this multicenter retrospective cohort analysis, SBRT of BoM from breast cancer was a well-tolerated, effective treatment. Prospective studies are needed to investigate these findings further and determine the role of standardized SBRT concepts in the multidisciplinary management of oligometastatic breast cancer.

Indexed as

Bone metastasesBreast cancerDose conceptMetastasis-directed therapy (MDT)SBRTSpine metastasesStereotactic body radiotherapyStereotactic radiotherapy

Identifiers

PMID41853739
PMCPMC12992980

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.